Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients’ Response to Immunotherapy

References

• Alhamarneh O, Amarnath SM, Stafford ND, Greenman J. 2008. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck. 30:251–261.
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Savani BN. 2006. Stem cell transplantation with reduced intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 20:1661–1672.
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Wang E, Sertoli MR, Marincola FM. 2010. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines. 9:555–565.
   PubMed Web of Science ®Google Scholar
• Belardelli F. 1995. Role of interferons and other cytokines in the regulation of the immune response (review). APMIS: Acta Pathologica, Microbiologica Et Immunologica Scandinavica. 103:101–179.
   Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. 1976. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458.
   PubMed Web of Science ®Google Scholar
• Brossart P. 2002. Dendritic cells in vaccination therapies of malignant diseases. Transfus Apher Sci. 27:183–186.
   PubMed Web of Science ®Google Scholar
• Buhmann R, Yang T, Grabrucker C, Liepert A, Kremser A, Dreyßig J, Kroell T, Schmid C, Tischer J, Kaiser S, et al. 2016. (in preparation). Dendritic cells can act as amplifiers of leukaemia-lysis or leukaemia-stimulation: a contribution to a refined functional analysis of partners involved in the mediation of anti-leukemic reactions.
   Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, et al. 2003. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Aqusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF. 1999. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 93:780–786.
   PubMed Web of Science ®Google Scholar
• Claxton DF, McMannis J, Champlin R, Choudhury A. 2001. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress. Crit Rev Immunol. 21:147–155.
   PubMed Web of Science ®Google Scholar
• de Greef GE, van Putten WL, Boogaerts M, Huijgens PC, Verdonck LF, Vellenga E, Theobald M, Jacky E, Löwenberg B. 2005. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK cooperative group studies. Br J Haematol. 128:184–191.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al. 2010. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474.
   PubMed Web of Science ®Google Scholar
• Dreyßig J, Kremser A, Liepert A, Grabrucker C, Freudenreich M, Schmid C, Kroell T, Scholl N, Tischer J, Kufner S, et al. 2011. Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes. Immunotherapy. 3:1113–1124.
   PubMed Web of Science ®Google Scholar
• Ferrara J, Levine J, Reddy P, Holler E. 2009. Graft-versus-host disease. The Lancet. 373:1550–1561.
   PubMed Web of Science ®Google Scholar
• Freudenreich M, Schmid C, Kremser A, Dreyßig J, Kroell T, Tischer J, Kolb HJ, Schmetzer HM. 2016. (in preparation). Clinical relevance of in vitro generated dendritic cells in patients with AML or MDS.
   Google Scholar
• Furukawa Y, Becker G, Stinn JL, Shimizu K, Libby P, Mitchell RN. 1999. Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical effects of Il-10 in vivo. Am J Pathol. 155:1929–1939.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Fitch FW. 1990. Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. J Immunol. 144:548–556.
   PubMed Web of Science ®Google Scholar
• Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. 2002. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother. 51:299–310.
   PubMed Web of Science ®Google Scholar
• Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL. 1999. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59:5356–5364.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjian HM. 2002. Acute myeloid leukemia. Hematology. 1:73–110.
   Google Scholar
• Grabrucker C, Liepert A, Dreyßig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer HM. 2010. The quality and quantity of leukemia-derived dendritic cells (DC) from patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are a predictive factor for the lytic potential of DC-primed leukemia-specific Tcells. J Immunother. 33:523–537.
   PubMed Web of Science ®Google Scholar
• Groux H, Bigler M, de Vries JE, Roncarolo MG. 1996. Interleukin-10 induces a long-term antigen-specific anergic state in Human CD4+ T cells. J Exp Med. 184:19–29.
   PubMed Web of Science ®Google Scholar
• Hayhoe FG. 1988. Classification of acute leukaemias. Blood Rev. 2:186–193.
   PubMed Web of Science ®Google Scholar
• Hehlgans T, Pfeffer K. 2005. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 115:1–20.
   PubMed Web of Science ®Google Scholar
• Hempel L, Körholz D, Nussbaum P, Bönig H, Burdach S, Zintl F. 1997. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant. 20:365–368.
   PubMed Web of Science ®Google Scholar
• Houssiau F, Van Snick J. 1992. IL6 and the T-cell response. Res Immunol. 143:740–743.
   PubMedGoogle Scholar
• Kammula US, Lee KH, Riker A, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM. 1999. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol. 163:6867–6875.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, et al. 2002. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the society for biological therapy. J Immunother. 25:97–138.
   PubMed Web of Science ®Google Scholar
• King C, Mueller Hoenger R, Malo Cleary M, Murali-Krishna K, Ahmed R, King E, Sarvetnick N. 2001. Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate cytotoxic CD8+ T-cell response. Nat Med. 7:206–214.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. 2010. IL-6: from its discovery to clinical applications. Int Immunol. 22:347–352.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood. 86:2041–2050.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schmid C, Barrett A, Schendel DJ. 2004. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 103:767–776.
   PubMed Web of Science ®Google Scholar
• Konieczny BT, Dai Z, Elwood ET, Saleem S, Linsley PS, Baddoura FK, Larsen CP, Pearson TC, Lakkis FG. 1998. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol. 160:2059–2064.
   PubMed Web of Science ®Google Scholar
• Kremser A, Dreyßig J, Grabrucker C, Liepert A, Kroell T, Scholl N, Schmid C, Tischer J, Kufner S, Salih H, et al. 2010. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother. 33:185–199.
   PubMed Web of Science ®Google Scholar
• Kufner S, Fleischer RP, Kroell T, Schmid C, Zitzelsberger H, Salih H, de Valle F, Treder W, Schmetzer HM. 2005. Serum-free generation and quantification of functionally active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother. 54:953–970.
   PubMed Web of Science ®Google Scholar
• Liepert A, Grabrucker C, Kremser A, Dreyßig J, Ansprenger C, Freudenreich M, Kroell T, Reibke R, Tischer J, Schweiger C, et al. 2010. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cell Immunol. 265:23–30.
   PubMed Web of Science ®Google Scholar
• Mazzolini G, Atorrasagasti C, Rizzo M, Murillo O, Dubrot J, Tirapu J, Arina A, Alfaro C, Azpilicueta A, Berasain C, et al. 2007. Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol. 13:5822–5831.
   PubMed Web of Science ®Google Scholar
• Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. 1993. Interleukin-10. Annu Rev Immunol. 11:165–190
   PubMed Web of Science ®Google Scholar
• Mosmann TR. 1992. T lymphocyte subsets, cytokines, and effector functions. Ann N Y Acad Sci. 664: 89–92.
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Takahashi H, Kanno Y, O’Shea JJ. 2012. Helper T cell diversity and plasticity. Curr Opin Immunol. 24: 297–302.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Paul WE. 2010. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 327:1098–1102.
   PubMed Web of Science ®Google Scholar
• Parronchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni MP, Macchia D, Maggi E, Del Prete G, Romagnani S. 1992. Il-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol. 149:2977–2983.
   PubMed Web of Science ®Google Scholar
• Peleman R, Wu J, Fargeas C, Delespesse G. 1989. Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Experiment Med. 170:1751–1756.
   PubMed Web of Science ®Google Scholar
• Quian S, Li W, Li Y, Fu F, Lu L, Fung JJ, Thomson AW. 1996. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation. 62:1709–1714.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Fredly H, Kittang AO, Bruserud O. 2013. The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins. 5:336–362.
   PubMed Web of Science ®Google Scholar
• Ritchie D, Seconi J, Wood C, Walton J, Watt V. 2005. Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 11:706–712.
   PubMed Web of Science ®Google Scholar
• Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, Waterfall M, Samuel K, Yin J, Johnson P, Turner M. 2006. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 133:152–157.
   PubMed Web of Science ®Google Scholar
• Romagnani S. 1992. Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? Immunol Today. 13:379–381.
   PubMedGoogle Scholar
• Roncarolo MG, Gregori S, Lucarelli B, Ciceri F, Bacchetta R. 2011. Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev. 241:145–163.
   PubMed Web of Science ®Google Scholar
• Salih HR, Nussler V. 2001. Commentary: Immune escape versus tumor tolerance: How do tumors evade immune surveillance? Eur J Med. Res6:323–332.
   PubMed Web of Science ®Google Scholar
• Savani BN, Labopin M, Blaise D, Niederwieser D, Ciceri F, Ganser A, Arnold R, Afanasyev B, Vigouroux S, Milpied N, et al. 2015. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia – A report from the ALWP of the EBMT. Haematologica [online] Available at: http://www.haematologica.org/content/101/2/256.long. doi:10.3324/haematol.2015.135699. Accessed on 13 December 2015.
   Google Scholar
• Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. 1995. CD28-B7 blockade after alloantigenic challenge in vivo inhibits TH1 cytokines but spares TH2. J Exp Med. 181:1869–1874.
   PubMed Web of Science ®Google Scholar
• Schmetzer HM, Kremser A, Loibl J, Kroell T, Kolb HJ. 2007. Quantification of ex vivo generated dendritic cells (DC) and leukemia derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation procedures ex vivo or in vivo. Leukemia. 21:1338–1341.
   PubMed Web of Science ®Google Scholar
• Schmetzer HM, Schmid C. 2012. The T-cells' Role in antileukemic reactions - Perspectives for future therapies. In: New advances in Stem Cell Transplantation, Demirer T (ed.). Chapter 4. Rijeka, Croatia: InTech, pp. 59–76.
   Google Scholar
• Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D. 2006. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 108:1092–1099.
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, et al. 2007. Acute leukemia working party: donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol. 25:4938–4945.
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, et al. 2011. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 119:1599–1606.
   PubMed Web of Science ®Google Scholar
• Smith KA. 1989. The interleukin 2 receptor. Annu Rev Cell Biol. 5:397–425.
   PubMedGoogle Scholar
• Stripecke R, Levine AM, Pullarkat V, Cardoso AA. 2002. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia. 16:1974–1983.
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Dighe AS, Gubler U, Murphy KM. 1997. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med. 185:817–824.
   PubMed Web of Science ®Google Scholar
• Tait BD. 2000. HLA class I expression on human cancer cells. Implications for effective immunotherapy. Hum Immunol. 61:158–165.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Ueki T, Sunaga S, Ikuta K, Sasaki Y, Li B, Moriyama N, Miyazaki J, Kawabe K. 1997. Murine interleukin 4 transgenic heart allograft survival prolonged with down-regulation of the TH1 cytokine mRNA in grafts. Transplantation. 64:152–157.
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Vlassara H, Cerami A. 1989. Cachectin/tumour necrosis factor. Lancet. 1:1122–1126.
   PubMed Web of Science ®Google Scholar
• Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nunez G, Tang A, Sayegh M, Hancock WW, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med. 5:1303–1307.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Tsuji T, Matsuzaki J, Zhange Y, Chamoto K, Kosaka A, Togashi Y, Sekikawa K, Sawada K, Takeshima T, et al. 2004. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity. Int Immunol. 16:811–817.
   PubMed Web of Science ®Google Scholar
• Yang YG, Wang H, Asavaroengchai W, Dey BR. 2005. Role of interferon-gamma in GVHD and GVL. Cell Mol Immunol. 2:323–329.
   PubMed Web of Science ®Google Scholar
• Zheng X, Steele A, Nickerson P, Steurer W, Steiger J, Strom TB. 1995. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol. 154:5590–5600.
   PubMed Web of Science ®Google Scholar